Earlier this week, Speaker of the House of Representatives Nancy Pelosi (D-CA) reached an agreement with President Donald Trump on passage of the United States-Mexico-Canada Agreement (USMCA), which if passed into law would replace the defunct and much maligned North American Free Trade Agreement (NAFTA). Not everyone is happy about the latest version of the USMCA agreed upon by the White House and House Democrats, including the U.S. Chamber of Commerce, which continues to support the overall agreement but has great concerns about the new provisions in the latest negotiated agreement between President Trump and Speaker Pelosi, which strikes expanded protection for biologic drugs from the agreement completely. Over the summer, House Democrats vocally opposed granting 10 years of regulatory data protection (RDP) for biologics inventions—an increase from 8 years in Canada and from 5 years in Mexico—arguing it would result in higher drug prices and delayed entry for biosimilars.
Business
- How Patents Helped Sprout the World’s First Plantable Pencil
- Patent Filings Roundup: Battle-Tested Off-Roading Patent Asserted; Jack Henry Battered Again
- When it Pays to Talk About Your Secrets
- Examining Samsung’s and LG’s LCD Patent Portfolios Following Decisions to Halt LCD Production
- DOJ Takes Key Step Toward Breaking Up Big Tech with Antitrust Complaint Against Google
Recent Posts
- Thought Experiment: Is Our Patent System Ready for a Potential Future of Brain Interfacing?
- How Patents Helped Sprout the World’s First Plantable Pencil
- Cybergenetics Appeals Ohio Federal Judge Ruling that Alice Kills DNA Analysis Patents
- We Made it to November: The IP Community Gives Thanks in a Year Like No Other
- Patent Filings Roundup: Battle-Tested Off-Roading Patent Asserted; Jack Henry Battered Again